Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Dissecting policy-making
Among professional Indian economists, C Rangarajan comes next only to Prime Minister Manmohan Singh in terms of the number of years spent in economic policy-making. His professional life, like that of the PM, began in academia. Both chose to be teachers and ended up in government. Both served as governors of the Reserve Bank of India (RBI). Both worked closely together during the crisis months of 1991-92. One went on to become prime minister, the other almost became union finance minister!

China Life may help in pre-IPO placement
Reliance Life is in talks with Chinese insurance giant China Life for a pre-initial public offer (IPO) placement. The Anil Dhirubhai Ambani group company is also in discussions with a private equity player for a total placement of 15 per cent stake.

News of the day

GM hoping to get 20% revenue from overseas markets
US car manufacturer General Motors today hoped to get 20 per cent revenue from overseas markets by 2011 once it starts exporting to these countries, a top company official said.
Online Business

Ranbaxy to sell Neronox in India

Ranbaxy Laboratories has entered into a licensing agreement with South Korean firm Medy-Tox Inc for selling its cosmetic product, Neuronox, in India. - Orchid gets USFDA nod for injection, gets 6-mth exclusivity - Glenmark raises Rs 413 cr through QIP - Suven Life gets two more US patents for NCEs - SC issues notices to Centre, others on Novartis petition - Road to recovery: Gujarat"s pharma share rises to 30% - Aurobindo Pharma receives Swissmedic approval The company in a statement to the Bombay Stock Exchange said, it will launch Medy-Tox"s anti-ageing medicine Neuronox in India to boost its presence in the dermatological segment. Commenting on the development Sanjeev Dani, Sr Vice President and Regional Director, Ranbaxy, said, “Neuronox comes as a welcome alternative to dermatologists in India and we aim to make botulinum toxin therapy more accessible and affordable to people in the country.” Ranbaxy scrip was trading at Rs 358, up 0.83 per cent on the Bombay Stock Exchange.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009